INTERNATIONAL NONPROPRIETARY NAME FOR ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY BAN2401 DECIDED AS LECANEMAB

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the International Nonproprietary Name (INN) for the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401 was decided as lecanemab. For details, please refer to the Recommended INN List No. 84 in WHO Drug Information Volume 34, No. 3.

For lecanemab, a global clinical Phase III study (Clarity AD) for early AD as well as a clinical Phase III study AHEAD 3-45 for preclinical AD are underway. Lecanemab is being jointly developed by Eisai and Biogen Inc. (Headquarters: Cambridge, Massachusetts, United States).

***